<b>Vicarius Pharma</b> Launches With $21.8 Million and Will be Helmed by Former Biogen-Elan Exec

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-investor.jpg" NAME"Vicarius Pharma Launches With $21.8 Million and Will be Helmed by Former Biogen-Elan Exec" ALT"Vicarius Pharma Launches With $21.8 Million and Will be Helmed by Former Biogen-Elan Exec"August…

Continue Reading<b>Vicarius Pharma</b> Launches With $21.8 Million and Will be Helmed by Former Biogen-Elan Exec

Ophthotech's Wet AMD Drug Fails to Meet Primary Endpoint in Phase III Study

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks2.jpg" NAME"Ophthotech's Wet AMD Drug Fails to Meet Primary Endpoint in Phase III Study" ALT"Ophthotech's Wet AMD Drug Fails to Meet Primary Endpoint in Phase III Study"August 14, 2017By…

Continue ReadingOphthotech's Wet AMD Drug Fails to Meet Primary Endpoint in Phase III Study

Tiny Virtual Biotech CellAct Forges $250 Million Chemo R&D Pact With Mundipharma

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-deal3.jpg" NAME"Tiny Virtual Biotech CellAct Forges $250 Million Chemo R&D Pact With Mundipharma" ALT"Tiny Virtual Biotech CellAct Forges $250 Million Chemo R&D Pact With Mundipharma"August 14, 2017By Alex Keown,…

Continue ReadingTiny Virtual Biotech CellAct Forges $250 Million Chemo R&D Pact With Mundipharma